Printer Friendly

DIANON SYSTEMS, INC. AND SCANTIBODIES COMBINE TO IMPROVE CLINICAL TESTING SERVICES

 STRATFORD, Conn., Jan. 12 /PRNewswire/ -- Dianon Systems, Inc. (NASDAQ: DIAN) announced today that an agreement has been reached with Scantibodies Laboratory, (Santee, Calif.) giving Dianon exclusive commercial laboratory rights to novel proprietary technology that promises to improve the reliability of certain laboratory procedures.
 Contaminating substances in specimens from some patients can interfere with many tests. Scientists at Scantibodies Laboratory have developed technology called Heterophilic Binding Reagent or HBR which appears to reduce or eliminate interferences without otherwise affecting the performance of these laboratory procedures.
 Analysis of hundreds of samples stored in Dianon's oncology specimen bank indicate that up to 5 percent of laboratory specimens may contain these interfering substances, collectively known as heterophile antibodies. A variety of methods for pretreating specimens to inactivate heterophile antibodies exist, but all are too expensive and impractical for general use. The procedure developed by Scantibodies Laboratory and employed exclusively at Dianon, appears to efficiently remove heterophile antibodies at an acceptable cost.
 Dianon is incorporating this technology into selected laboratory procedures with the intent of extending this service to clients in 1993.
 Scantibodies Laboratory has been providing critical components and services to diagnostic kit manufacturers since 1976.
 -0- 1/12/93
 /CONTACT: Richard A. Sandberg, chairman and co-chief executive officer of Dianon Systems, Inc., 203-381-4022, Tom Cantor, president of Scantibodies Laboratory, Inc., 619-258-9300,
 (DIAN)


CO: Dianon Systems, Inc.; Scantibodies Laboratory ST: Connecticut, California IN: MTC SU:

TS -- NY111 -- 4252 01/12/93 18:30 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 12, 1993
Words:240
Previous Article:ADDITIONAL CHARGES FILED IN CONNECTION WITH DEVELOPMENT OF EAST BOSTON GUMBALL FACTORY
Next Article:DIANON SYSTEMS, INC. AND DIAGNOSTIC TECHNOLOGIES, INC. COMBINE TO EVALUATE PREGNANCY MONITORING PROCEDURE
Topics:


Related Articles
DIANON SYSTEMS SELECTED AS ANALYST'S NO. 1 HEALTH CARE COMPANY AT THE HAMBRECHT & QUIST HEALTH CARE CONFERENCE
DIANON SYSTEMS, INC. AND DIAGNOSTIC TECHNOLOGIES, INC. COMBINE TO EVALUATE PREGNANCY MONITORING PROCEDURE
DIANON SYSTEMS, INC. ACQUIRES EXCLUSIVE RIGHTS TO A UNIQUE CANCER TEST FROM M.D. ANDERSON CANCER CENTER
DIANON SYSTEMS, INC. AND CENTOCOR, INC. ANNOUNCE PRODUCT DEVELOPMENT AGREEMENT
DIANON SYSTEMS, INC. SIGNS AGREEMENT WITH JAPANESE LABORATORY FOR GENETIC TESTING
DIANON Systems, Inc. Proposes A Business Combination With UroCor, Inc.
DIANON Systems Announces Results from Largest Studies to Date of New Prostate Cancer Test - Development of A Statistical Model to Reduce Number of...
DIANON Systems, Inc. Announces Agreement to Provide Laboratory Services for Oxford Health Plans, Inc.
ARUP Laboratories and Scantibodies Clinical Laboratory Announce Availability of Improved Parathyroid Disease Test.
Laboratory Corporation of America(R) Announces Definitive Agreement To Acquire DIANON Systems, Inc.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters